NIOSH Testimony on Occupational Exposure to 1,3-Butadiene by J. D. Millar, February 10, 1992.
NIOSH 1992 Feb:6 pages
This post hearing brief concerned the viewpoints of NIOSH regarding laboratory experiments using animals to determine the effects of 1,3- butadiene (106990) (BD). The first area of concern was the use of quantitative risk estimates for butadiene which the Chemical Manufacturers Association (CMA) indicated should be based on the International Institute of Synthetic Rubber Producers, Inc. rat study rather than the low dose National Toxicology Program mouse study. The second point considered was that CMA considered studies of BD uptake which demonstrated that primates retain only 1/10 or 1/30 as much BD as B6C3F1-mice on a per kilogram basis to indicate that humans would be 1/10 or 1/30 as sensitive to BD induced cancers as B6C3F1-mice. The third concern was that CMA concluded that since 1,2-epoxybutene-3 levels are about 500 times lower in primates than in B6C3F1-mice, humans would be expected to be 500 times less susceptible to BD induced cancer. The last point was the advisability of using BW(3/4) scaling from B6C3F1-mice to humans.
NIOSH-Author; NIOSH-Testimony; Millar-J-D; Risk-analysis; Risk-factors; Laboratory-animals; Dienes; Cancer-rates; Comparative-toxicology;
NTIS Accession No.
NIOSH, 6 pages, 13 references